Fund Exits Insmed After Disappointing Uptake of Brinsupri
American Century Investments Focused Dynamic Growth Fund exited its position in Insmed, a clinical-stage biotech developing therapies for serious rare diseases, during the second quarter of 2026. The letter cited disappointing uptake of Brinsupri despite a large unmet medical need. Insmed shares fell about 11.65% over the past year, though they rose 1.96% in the past month.